Skip to search formSkip to main contentSkip to account menu

terutroban

Known as: 3-((6-amino-(4-chlorobenzenesulfonyl)-2-methyl-5,6,7,8-tetrahydronapht)-1-yl)propionic acid 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

NaphthalenesPropionates

Narrower (2)

S 18204S-18886

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis
Background The latest guidelines do not make clear recommendations on the selection of antiplatelet therapies for long-term… 
2014
2014
Blockade of endothelin ET(A), but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions.
2012
2012
Advances in prevention and health services delivery 2010-2011.
SStroke mortality has decreased, in large part because of better prevention. There are several new treatment options for patients… 
2010
2010
Terutroban, a Thromboxane/Prostaglandin Endoperoxide Receptor Antagonist, Increases Survival in Stroke-Prone Rats by Preventing Systemic Inflammation and Endothelial Dysfunction: Comparison with…
This study investigated the efficacy of terutroban, a specific thromboxane/prostaglandin endoperoxide receptor antagonist, on… 
2009
2009
Effect of the Thromboxane Prostaglandin Receptor Antagonist Terutroban on Arterial Thrombogenesis after Repeated Administration in Patients Treated for the Prevention of Ischemic Stroke
Background: The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin… 
Highly Cited
2008
Highly Cited
2008
Two isoforms of cyclooxygenase contribute to augmented endothelium-dependent contractions in femoral arteries of 1-year-old rats
AbstractAim:The present experiments were designed to study the changes in endothelium-dependent contractions with aging.Methods… 
Highly Cited
2008
Highly Cited
2008
The role of prostaglandin E and thromboxane-prostanoid receptors in the response to prostaglandin E2 in the aorta of Wistar Kyoto rats and spontaneously hypertensive rats.
AIMS The present study examined the hypothesis that prostaglandin E2 (PGE2) through activation of prostaglandin E (EP) receptor… 
2007
2007
Renal Effects of S18886 (Terutroban), a TP Receptor Antagonist, in an Experimental Model of Type 2 Diabetes
Thromboxane A2 (TxA2) is assumed to contribute to the development of diabetes complications, including nephropathy. We… 
2007
2007
The Selective TP Receptor Antagonist, S18886 (Terutroban), Attenuates Renal Damage in the Double Transgenic Rat Model of Hypertension
Background/Aims: Thromboxane receptors play a decisive role in the renovascular actions of angiotensin II. We studied the… 
2007
2007
New developments in oral antiplatelet therapy
Oral antiplatelet therapy is central to the treatment of patients with thrombotic diseases. Yet, despite the proven efficacy of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)